Comparing myofascial release and percutaneous electrical nerve stimulation in plantar fasciitis: A randomised controlled trial

Authors

  • Hamsa Geetha BoobalanDepartment of Musculoskeletal Sciences, College of Physiotherapy, Saveetha Institute of Medical and Technical Sciences, Chennai, India 
  • Ramana KameswaranDepartment of Musculoskeletal Sciences, College of Physiotherapy, Saveetha Institute of Medical and Technical Sciences, Chennai, India 

DOI:

Keywords

plantar fasciitis, myofascial release, percutaneous electrical nerve stimulation

Correspondence

Hamsa Geetha Boobalan
Email: dhanalakshmib591@gmail.com

Publication history

Received: 6 Jan 2026
Accepted: 4 May 2026
Published online: 10 May 2026

Responsible editor

Reviewers

A: Md Nuruzzaman Khandaker
B: Mohammad Tariqul Islam

Funding

None

Ethical approval

Approved by Institutional Scientific Review Board of Saveetha Institute of Medical and Technical Sciences (No. ISRB No: 07/032/2024/ISRB/UGSR/SCPT, Dated 14 Dec 2023).

Trial registration number

Not applicable

Copyright

© The Author(s) 2026; all rights reserved. 
Published by Bangladesh Medical University (former Bangabandhu Sheikh Mujib Medical University).
Key messages
Myofascial release and percutaneous electrical nerve stimulation both improve pain and function in plantar fasciitis. Myofascial release demonstrated superior reduction in pain and greater functional improvement compared with percutaneous electrical nerve stimulation after four weeks of intervention.

Plantar fasciitis is a common cause of inferior heel pain, frequently affecting individuals aged 40–60 years and leading to impaired mobility and reduced quality of life. Conservative physiotherapy remains the first-line management, with interventions targeting tissue mechanics and pain modulation [1]. Myofascial release aims to reduce fascial restrictions and improve tissue extensibility, whereas percutaneous electrical nerve stimulation primarily provides neuromodulatory analgesia. Comparative evidence between these approaches remains limited [2]. This study compared the effectiveness of myofascial release and percutaneous electrical nerve stimulation in reducing pain and improving functional performance in individuals with plantar fasciitis.

A randomized comparative study was conducted among 36 participants aged 40–60 years with clinically diagnosed plantar fasciitis. Participants were randomly allocated into two groups: myofascial release (n = 18) and percutaneous electrical nerve stimulation (n = 18). Interventions were administered for 30 minutes, twice weekly for four weeks. The myofascial release group received sustained manual release techniques targeting the plantar fascia, gastrocnemius, and soleus muscles. The percutaneous electrical nerve stimulation group received electrical stimulation via percutaneously inserted needles along the medial calcaneal nerve and plantar fascia region [3]. Pain intensity and functional performance were assessed using the Visual Analogue Scale and Foot and Ankle Disability Index. Paired t-tests were used to analyze pre- and post-intervention differences, with statistical significance set at P < 0.05 [4].

Both groups demonstrated significant improvements following treatment. In the myofascial release group, mean Visual Analogue Scale scores decreased from 7.0 (0.8) to 4.7 (0.8), and Foot and Ankle Disability Index scores improved from 51.1 (6.0) to 91.9 (3.4). In the percutaneous electrical nerve stimulation group, Visual Analogue Scale scores reduced from 7.0 (0.8) to 5.7 (0.8), while Foot and Ankle Disability Index scores improved from 51.1 (6.0) to 83.9 (2.5). Between-group comparison showed greater improvement in pain reduction and functional performance in the myofascial release group compared with the percutaneous electrical nerve stimulation group.

Table 1 Within-group comparison of pre- and post-Intervention visual analogue scale and foot and ankle disability index scores

Outcome

Pre-test

Post-test

P

Visual analogue scale

Myofascial release

7.0  (0.8) 

4.7 (0.8) 

0.001  

Percutaneous electrical nerve stimulation

7.0 (0.8)

5.7 (0.8)

0.001

Foot and ankle disability index

Myofascial release 

51.1 (6.0) 

91.9 (3.4)

0.001

Percutaneous electrical nerve stimulation 

51.1 (6.0)  

83.9 (2.5)

0.001

Results are mean (standard deviation)

Both interventions were effective in managing plantar fasciitis, consistent with previous evidence supporting fascial mobilization and neuromodulator techniques. Improvements observed in the myofascial release group may be attributed to reduced fascial stiffness, improved tissue glide, and decreased tensile stress at the calcaneal insertion. percutaneous electrical nerve stimulation demonstrated early analgesic effects likely mediated through peripheral nerve stimulation and pain modulation [5]. The greater functional improvement seen with myofascial release suggests that mechanical restoration of tissue properties may produce sustained benefits beyond pain relief alone [6].

These findings highlight the complementary roles of both modalities. percutaneous electrical nerve stimulation may be useful for rapid pain reduction, whereas myofascial release appears to provide progressive functional recovery. A multimodal rehabilitation approach combining both techniques may optimize clinical outcomes. Limitations include small sample size and short intervention duration. Further studies with longer follow-up are recommended.

In conclusion, both myofascial release and percutaneous electrical nerve stimulation effectively reduced pain and improved functional performance in individuals with plantar fasciitis. However, myofascial release demonstrated superior clinical outcomes and may be considered a preferred conservative intervention.

Variables  

Frequency (%)

Indication of colposcopy

 

Visual inspection of the cervix with acetic acid positive

200 (66.7)

Abnormal pap test

13 (4.3)

Human papilloma virus DNA positive

4 (1.3)

Suspicious looking cervix

14 (4.7)

Others (per vaginal discharge, post-coital bleeding)

69 (23.0)

Histopathological diagnosis

Cervical Intraepithelial Neoplasia 1

193 (64.3)

Cervical Intraepithelial Neoplasia 2

26 (8.7)

Cervical Intraepithelial Neoplasia 3

32 (10.7)

Invasive cervical cancer

27 (9.0)

Chronic cervicitis

17 (5.6)

Squamous metaplasia

5 (1.7)

Groups based on pre-test marks

Pretest
marks (%)

Posttest

Marks (%)

Difference in pre and post-test marks (mean improvement)

P

Didactic lecture classes

<50%

36.6 (4.8)

63.2 (9.4)

26.6

<0.001

≥50%

52.8 (4.5)

72.4 (14.9)

19.6

<0.001

Flipped classes

<50%

36.9 (4.7)

82.2 (10.8)

45.4

<0.001

≥50%

52.8 (4.6)

84.2 (10.3)

31.4

<0.001

Data presented as mean (standard deviation)

Background characteristics

Number (%)

Age at presentation (weeks)a

14.3 (9.2)

Gestational age at birth (weeks)a

37.5 (2.8)

Birth weight (grams)a

2,975.0 (825.0)

Sex

 

Male

82 (41)

Female

118 (59)

Affected side

 

Right

140 (70)

Left

54 (27)

Bilateral

6 (3)

Delivery type

 

Normal vaginal delivery

152 (76)

Instrumental delivery

40 (20)

Cesarean section

8 (4)

Place of delivery

 

Home delivery by traditional birth attendant

30 (15)

Hospital delivery by midwife

120 (60)

Hospital delivery by doctor

50 (25)

Prolonged labor

136 (68)

Presentation

 

Cephalic

144 (72)

Breech

40 (20)

Transverse

16 (8)

Shoulder dystocia

136 (68)

Maternal diabetes

40 (20)

Maternal age (years)a

27.5 (6.8)

Parity of mother

 

Primipara

156 (78)

Multipara

156 (78)

aMean (standard deviation), all others are n (%)

Background characteristics

Number (%)

Age at presentation (weeks)a

14.3 (9.2)

Gestational age at birth (weeks)a

37.5 (2.8)

Birth weight (grams)a

2,975.0 (825.0)

Sex

 

Male

82 (41)

Female

118 (59)

Affected side

 

Right

140 (70)

Left

54 (27)

Bilateral

6 (3)

Delivery type

 

Normal vaginal delivery

152 (76)

Instrumental delivery

40 (20)

Cesarean section

8 (4)

Place of delivery

 

Home delivery by traditional birth attendant

30 (15)

Hospital delivery by midwife

120 (60)

Hospital delivery by doctor

50 (25)

Prolonged labor

136 (68)

Presentation

 

Cephalic

144 (72)

Breech

40 (20)

Transverse

16 (8)

Shoulder dystocia

136 (68)

Maternal diabetes

40 (20)

Maternal age (years)a

27.5 (6.8)

Parity of mother

 

Primipara

156 (78)

Multipara

156 (78)

aMean (standard deviation), all others are n (%)

Mean escape latency of acquisition day

Groups                 

NC

SC

ColC

Pre-SwE Exp

Post-SwE Exp

Days

 

 

 

 

 

1st

26.2 (2.3)

30.6 (2.4) 

60.0 (0.0)b

43.2 (1.8)b

43.8 (1.6)b

2nd

22.6 (1.0) 

25.4 (0.6)

58.9 (0.5)b

38.6 (2.0)b

40.5 (1.2)b

3rd

14.5 (1.8) 

18.9 (0.4) 

56.5 (1.2)b

34.2 (1.9)b 

33.8 (1.0)b

4th

13.1 (1.7) 

17.5 (0.8) 

53.9 (0.7)b

35.0 (1.6)b

34.9 (1.6)b

5th

13.0 (1.2) 

15.9 (0.7) 

51.7 (2.0)b

25.9 (0.7)b 

27.7 (0.9)b

6th

12.2 (1.0) 

13.3 (0.4) 

49.5 (2.0)b

16.8 (1.1)b

16.8 (0.8)b

Average of acquisition days

5th and 6th 

12.6 (0.2)

14.6 (0.8)

50.6 (0.7)b

20.4 (2.1)a

22.4 (3.2)a

NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure.

aP <0.05; bP <0.01.

Categories

Number (%)

Sex

 

   Male

36 (60.0)

   Female

24 (40.0)

Age in yearsa

8.8 (4.2)

Education

 

   Pre-school

20 (33.3)

   Elementary school

24 (40.0)

   Junior high school

16 (26.7)

Cancer diagnoses

 

Acute lymphoblastic leukemia

33 (55)

Retinoblastoma

5 (8.3)

Acute myeloid leukemia

4 (6.7)

Non-Hodgkins lymphoma

4 (6.7)

Osteosarcoma

3 (5)

Hepatoblastoma

2 (3.3)

Lymphoma

2 (3.3)

Neuroblastoma

2 (3.3)

Medulloblastoma

1 (1.7)

Neurofibroma

1 (1.7)

Ovarian tumour

1 (1.7)

Pancreatic cancer

1 (1.7)

Rhabdomyosarcoma

1 (1.7)

aMean (standard deviation)

Test results

Disease

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

Yes

No

Reid’s score ≥ 5

Positive

10

15

37.0

94.5

40.1

93.8

Negative

17

258

 

 

 

 

Swede score ≥ 5

Positive

20

150

74.1

45.0

11.8

94.6

Negative

7

123

 

 

 

 

Swede score ≥ 8

Positive

3

21

11.1

92.3

12.5

91.3

Negative

24

252

 

 

 

 

High-grade indicates a score of ≥5 in both tests; PPV indicates positive predictive value; NPV, negative predictive value

Test

Sensitivity (%)

Specificity (%)

Positive predictive value (%)

Negative predictive value (%)

Reid’s score ≥ 5

37.0

94.5

40.0

93.8

Swede score ≥ 5

74.1

45

11.8

94.6

Swede score ≥ 8

11.1

92.3

12.5

91.3

Test

Sensitivity (%)

Specificity (%)

Positive predictive value (%)

Negative predictive value (%)

Reid’s score ≥ 5

37.0

94.5

40.0

93.8

Swede score ≥ 5

74.1

45

11.8

94.6

Swede score ≥ 8

11.1

92.3

12.5

91.3

Narakas classification

Total

200 (100%)

Grade 1

72 (36%)

Grade 2

64 (32%)

Grade 3

50 (25%)

Grade 4

14 (7%)

Complete recoverya

107 (54)

60 (83)

40 (63)

7 (14)

-

Near complete functional recovery but partial deformitya

22 (11)

5 (7)

10 (16)

6 (12)

1 (7)

Partial recovery with gross functional defect    and deformity

31 (16)

7 (10)

13 (20)

10 (20)

1 (7)

No significant improvement 

40 (20)

-

1 (1.5)

27 (54)

12 (86)

aSatisfactory recovery

bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7, 8, 9, Grade 4, panpalsy with Hornon’s syndrome.

Narakas classification

Total

200 (100%)

Grade-1

72 (36%)

Grade-2

64 (32%)

Grade-3

50 (25%)

Grade-4

14 (7%)

Complete recoverya

107 (54)

60 (83)

40 (63)

7 (14)

-

Near complete functional recovery but partial deformitya

22 (11)

5 (7)

10 (16)

6 (12)

1 (7)

Partial recovery with gross functional defect    and deformity

31 (16)

7 (10)

13 (20)

10 (20)

1 (7)

No significant improvement 

40 (20)

-

1 (1.5)

27 (54)

12 (86)

aSatisfactory recovery

bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7,8,9, Grade 4, panpalsy with Hornon’s syndrome.

Variables in probe trial day

Groups

NC

SC

ColC

Pre-SwE Exp

Post-SwE Exp

Target crossings

8.0 (0.3)

7.3 (0.3) 

1.7 (0.2)a

6.0 (0.3)a

5.8 (0.4)a

Time spent in target

18.0 (0.4) 

16.2 (0.7) 

5.8 (0.8)a

15.3 (0.7)a

15.2 (0.9)a

NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure.

aP <0.01.

Pain level

Number (%)

P

Pre

Post 1

Post 2

Mean (SD)a pain score

4.7 (1.9)

2.7 (1.6)

0.8 (1.1)

<0.001

Pain categories

    

   No pain (0)

-

(1.7)

31 (51.7)

<0.001

   Mild pain (1-3)

15 (25.0)

43 (70.0)

27 (45.0)

 

   Moderete pain (4-6)

37 (61.7)

15 (25.0)

2 (3.3)

 

   Severe pain (7-10)

8 (13.3)

2 (3.3)

-

 

aPain scores according to the visual analogue scale ranging from 0 to 10; SD indicates standard deviation

Surgeries

Number  

(%)

Satisfactory outcomes n (%)

Primary surgery (n=24)

 

 

Upper plexus

6 (25)

5 (83)

Pan-palsy

18 (75)

6 (33)

All

24 (100)

11 (46)

Secondary Surgery (n=26)

 

 

Shoulder deformity

15 (58)

13 (87)

Wrist and forearm deformity

11 (42)

6 (54)

All

26 (100)

19 (73)

Primary and secondary surgery

50 (100)

30 (60)

Mallet score 14 to 25 or Raimondi score 2-3 or Medical Research grading >3 to 5.

Narakas classification

Total

200 (100%)

Grade-1

72 (36%)

Grade-2

64 (32%)

Grade-3

50 (25%)

Grade-4

14 (7%)

Complete recoverya

107 (54)

60 (83)

40 (63)

7 (14)

-

Near complete functional recovery but partial deformitya

22 (11)

5 (7)

10 (16)

6 (12)

1 (7)

Partial recovery with gross functional defect    and deformity

31 (16)

7 (10)

13 (20)

10 (20)

1 (7)

No significant improvement 

40 (20)

-

1 (1.5)

27 (54)

12 (86)

aSatisfactory recovery

bGrade 1, C5, 6, 7 improvement; Grade 2, C5, 6, 7 improvement; Grade 3, panpalsy C5, 6, 7,8,9, Grade 4, panpalsy with Hornon’s syndrome.

Trials

Groups

NC

SC

ColC

Pre-SwE Exp

Post-SwE Exp

1

20.8 (0.6)

22.1 (1.8)

41.1 (1.3)b

31.9 (1.9)b

32.9 (1.8)a, b

2

10.9 (0.6)

14.9 (1.7)

37.4 (1.1)b

24.9 (2.0)b

26.8 (2.5)b

3

8.4 (0.5)

9.9 (2.0)

32.8 (1.2)b

22.0 (1.4)b

21.0 (1.4)b

4

7.8 (0.5)

10.4 (1.3)

27.6(1.1)b

12.8 (1.2)b

13.0 (1.4)b

Savings (%)c

47.7 (3.0)

33.0 (3.0)

10.0 (0.9)b

23.6 (2.7)b

18.9 (5.3)b

NC indicates normal control; SC, Sham control; ColC, colchicine control; SwE, swimming exercise exposure.

aP <0.05; bP <0.01.

cThe difference in latency scores between trials 1 and 2, expressed as the percentage of savings increased from trial 1 to trial 2

 Lesion-size

Histopathology report

Total

CIN1

CIN2

CIN3

ICC

CC

SM

0–5 mm

73

0

0

0

5

5

83

6–15 mm

119

18

1

4

0

0

142

>15 mm

1

8

31

23

12

0

75

Total

193

26

32

27

17

5

300

CIN indicates cervical intraepithelial neoplasia; ICC, invasive cervical cancer; CC, chronic cervicitis; SM, squamous metaplasia

 

Histopathology report

Total

CIN1

CIN2

CIN3

ICC

CC

SM

Lesion -Size

0-5  mm

73

0

0

0

5

5

83

6-15  mm

119

18

1

4

0

0

142

>15  mm

1

8

31

23

12

0

75

Total

193

26

32

27

17

5

300

CIN indicates Cervical intraepithelial neoplasia; ICC, Invasive cervical cancer; CC, Chronic cervicitis; SM, Squamous metaplasia

Group

Didactic posttest marks (%)

Flipped posttest marks (%)

Difference in marks (mean improvement)

P

<50%

63.2 (9.4)

82.2 (10.8)

19.0

<0.001

≥50%

72.4 (14.9)

84.2 ( 10.3)

11.8

<0.001

Data presented as mean (standard deviation)

Acknowledgements
The authors thank all participants who took part in the study.
Author contributions
aManuscript drafting and revising it critically: HG, RK. Approval of the final version of the manuscript: HG, RK. Guarantor of accuracy and integrity of the work: HG, RK.
Conflict of interest
We do not have any conflict of interest.
Data availability statement
We confirm that the data supporting the findings of the study will be shared upon reasonable request.
AI disclosure
No generative AI tools were used in manuscript preparation beyond language editing assistance.
Supplementary file
None
    References
    1. Ozdemir H, Söyüncü Y, Ozgörgen M, Dabak K. Effects of changes in heel fat pad thickness and elasticity on heel pain. J Am Podiatr Med Assoc. 2004 Jan-Feb;94(1):47-52. doi: 10.7547/87507315-94-1-47. PMID: 14729991
    2. Goweda R, Alfalogy E, Filfilan R, Hariri G. Prevalence and risk factors of plantar fasciitis among patients with heel pain attending primary health care centers of Makkah, Kingdom of Saudi Arabia. J High Inst Public Health. 2015;45(2):71–75. Available at: https://pdfs.semanticscholar.org/2e77/a0af5056d8de3ebd405e87eb146b62981307.pdf. [Accessed on 5 May 2026]
    3. Rarassanti G, Saraswati P, Dewi A. Factors contributing to plantar fasciitis in women. Phys Ther J Indones. January-June, 2022;3(1) 1-5. doi: https://doi.org/10.51559/ptji.v3i1.46
    4. Riddle DL, Pulisic M, Pidcoe P, Johnson RE. Risk factors for Plantar fasciitis: a matched case-control study. J Bone Joint Surg Am. 2003 May;85(5):872-7. doi: 10.2106/00004623-200305000-00015. Erratum in: J Bone Joint Surg Am. 2003 Jul;85-A(7):1338. PMID: 12728038
    5. Saltzman CL, Domsic RT, Baumhauer JF, Deland JT, Gill LH, Hurwitz SR, Kitaoka HB, McClouskey LC, Porter D. Foot and ankle research priority: report from the Research Council of the American Orthopaedic Foot and Ankle Society. Foot Ankle Int. 1997 Jul;18(7):447-8. doi: 10.1177/107110079701800714
    6. Martin RL, Burdett RG, Irrgang JJ. Development of the foot and ankle disability index (FADI). J Orthop Sports Phys Ther. 1999;29(1):A32–A33. Available at: https://www.scirp.org/reference/referencespapers?referenceid=1796682. [Accessed on 5 May 2026]